- Home
- / Arrowhead Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Arrowhead Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$20
2024-10-29
Market Capitalization
$2.5 B
2024-10-29
Revenue
$829.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 138.3M | 243.2M | 240.7M | 3.6M | 829.4M |
| General and administrative expense | 81.0M | 124.4M | 92.5M | 98.8M | 123.9M |
| Operating expense total | 287.3M | 421.7M | 445.7M | 604.6M | 731.1M |
| EBIT | (149.0M) | (178.5M) | (205.0M) | (601.1M) | 98.3M |
| EBIT margin, % | -107.8% | -73.4% | -85.2% | -16927.1% | 11.9% |
| Investment income | 22.7M | 37.3M | |||
| Interest income | 6.1M | 5.0M | 15.3M | 22.7M | 37.3M |
| Interest expense | 18.3M | 19.0K | |||
| Pre tax profit | (140.8M) | (172.7M) | (206.5M) | (612.5M) | 51.5M |
| Income tax expense | 2.0K | 3.8M | 2.8M | (2.8M) | 21.4M |
| Net Income | (140.8M) | (176.5M) | (209.3M) | (609.7M) | 30.1M |
| EPS | (1.4) | (1.7) | (1.9) | (5.0) | 0.0 |